Noninvasive Down syndrome test
This article was originally published in The Gray Sheet
Executive SummarySan Diego-based genomics firm Sequenom announces new data supporting its noninvasive prenatal Down syndrome lab-developed test, which it expects to be commercially available through licensing partners in the first half of 2009. In preliminary studies of more than 100 clinical plasma specimens tested on the firm's MassArray platform using its SEQureDx technology, the test approached 95% sensitivity and 99% specificity, Sequenom says. The test uses a maternal blood sample and can be done earlier than invasive procedures such as amniocentesis
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.